Archives de l’auteur : osivax
LABIOTECH.eu – French Startup’s Universal Flu Vaccine Development Boosted by €8M Series A
FierceBiotech – Osivax raises €8M for universal flu vaccine clinical trials
Osivax secures EUR 8 Million of Financing through a Series A Round
Osivax Secures EUR 8 Million of Financing through a Series A Round to Develop Novel Universal Flu Vaccines and Expand oligoDOM® Technology Platform — Company to establish new subsidiary office in Liege, Belgium — Lyon, France – July 10, 2019 – Osivax announced today that it has secured EUR 8 million of financing through a Series …
Continuer la lecture « Osivax secures EUR 8 Million of Financing through a Series A Round »
Osivax appoints Dr. Paul Willems as Chief Medical Officer
Paul Willems’ appointment will strengthen Osivax’s capacities to design and implement an ambitious and impactful clinical development plan for its vaccines pipeline and especially the “universal” flu vaccine program Lyon, France – January 31st, 2019 – Osivax, a clinical stage biopharmaceutical company currently focused on the development of a breakthrough “universal” influenza vaccine program, announced today …
Continuer la lecture « Osivax appoints Dr. Paul Willems as Chief Medical Officer »
LABIOTECH.eu – This Newly Founded French Biotech is All About Vaccines
Approval of Osivax’ First in Human Clinical Trial for its Universal Influenza Vaccine Candidate
Osivax announces that the Belgian health authority approved the initiation of a first-in-human clinical trial evaluating the safety and immunogenicity of OVX836 in healthy volunteers Lyon, France – June 4, 2018 – Osivax, a clinical stage biopharmaceutical company currently focused on the development of a universal influenza vaccine candidate, announced today that the Belgian health authority …
LeProgres – Le vaccin contre la grippe d’Osivax pourrait générer plus d’un milliard par an
Osivax strengthens its collaboration with the German Cancer Research Center (DKFZ)
As DKFZ’s HPV vaccine candidate based on Osivax’s technology platform (OVX313) reports promising pre-clinical results, a second license agreement was signed Lyon, France – April 17, 2018 – Osivax, a biopharmaceutical company currently focused on the development of a universal influenza vaccine candidate, announced today the reinforcement of its collaboration with the world-renowned German Cancer Research …
Osivax appoints Prof. Jeffrey Almond, pre-eminent Vaccinologist, as Chairman of its Scientific Advisory Board
Prof. Almond’s appointment will strengthen Osivax’s capacities to drive, position and prioritize pipeline development and especially OVX836, a broad-spectrum influenza vaccine Lyon, France – February 19th, 2018 – Osivax, a biopharmaceutical company currently focused on the development of a breakthrough influenza vaccine, announced today that the Company is strengthening its management team with the appointment of …